
Accolades
Testimonials
Collated independently by Legal 500 research team.
‘Very strong knowledge in technology-driven life sciences, including unique aspects of such a regulated industry (FDA, etc.). Particularly strong knowledge and experience in public securities offerings in the life sciences.’
‘After my 35 years in the medical device industry and 3 IPOs, I believe Shayne Kennedy has more relevant experience than any other lawyer at any firm.’
Key clients
- 4D Molecular Therapeutics
- AbbVie
- Actelion
- Aiolos Bio
- Alkermes
- Arcutis Biotherapeutics
- Artelon
- Ascendis Pharma
- Avidity Biosciences
- BioXcel Therapeutics
Work highlights
- Advised CARGO Therapeutics in its IPO of 18,750,000 Shares of Common Stock listed on Nasdaq.
- Advised CG Oncology in its IPO of 20,000,000 Shares of Common Stock listed on Nasdaq.
- Advised Cerevel Therapeutics, a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses, in its acquisition by AbbVie Inc. for US$8.7 billion, including an FTC Second Request clearance.
Lawyers
Hall of fame
The lawyers at the very top of the profession, widely known and respected by peers and clients for their longstanding involvement in market-leading work.

Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Next generation partners
Junior partners with significant recognition from clients and peers in the market and key roles on multiple matters.
Practice head
Shayne Kennedy; John Manthei; Arlene Chow; Terra Reynolds
Other key lawyers
Ben Haas; Julie Scallen; Cheston Larson; Elizabeth Richards; Matthew Bush; Nathan Ajiashvili; William McConagha; Jennifer Bragg; Kate Hillier